Research programme: type 2 diabetes mellitus therapeutics - AlbireoAlternative Names: IBAT inhibitor (for T2DM) - Albireo
Latest Information Update: 12 Jan 2017
At a glance
- Originator Albireo
- Developer Albireo Pharma
- Mechanism of Action Sodium-bile acid cotransporter-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 18 Dec 2014 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)